Clinical trial · Interventional
The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma
NCT02418390CI-TRIAL-00058840completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to investigate the efficacy and safety of prophylactic central lymph node dissection in papillary thyroid carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer, Papillary | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| prophylactic central lymph node dissection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- No prophylactic central dissection
- description
- Patients underwent total thyroidectomy for papillary thyroid carcinoma, without prophylactic central lymph node dissection
- type
- ACTIVE_COMPARATOR
- label
- Prophylactic central dissection
- description
- Patients underwent total thyroidectomy for papillary thyroid carcinoma, with prophylactic central lymph node dissection
- interventionNames
- Procedure: prophylactic central lymph node dissection
Primary outcomes (3)
- measure
- The number of participants with successful surgical completeness
- timeFrame
- Participants will be followed from the operation to 5 year (maximum)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion criteria were as follows: 1. patients aged 20 to 70 years old 2. patients diagnosed with PTC or suspicious for PTC on fine needle aspiration or core needle biopsy 3. patients with no evidence of LNM before and during surgery(cN0) 4. patients with no evidence of distant metastasis(cM0). Exclusion criteria were as follows: 1. patients suspected of advanced PTC(clinically T3 or T4) such as invasion of peripheral organs on preoperative examination 2. patients who have previous history of cervical radiation therapy or surgery. 3. pregnant women 4. uncontrolled diabetes, hypertension, or chronic renal failure 5. aspirin or anticoagulant medication within 7 days 6. other clinical trial participation within 30 days 7. radiation exposure to the head and neck 8. previous operation to the neck 9. advanced thyroid cancer including adjacent organ invasion
References
Publications (1)
- RESULTCarling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, Kloos RT, Mazzaferri EL Sr, Peduzzi PN, Roman SA, Sippel RS, Sosa JA, Stack BC Jr, Steward DL, Tufano RP, Tuttle RM, Udelsman R; American Thyroid Association Surgical Affairs Committee. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid. 2012 Mar;22(3):237-44. doi: 10.1089/thy.2011.0317. Epub 2012 Feb 7. PMID 22313454